Cancer Treatment Reviews
Volume 31, Issue 3 , Pages 210-225 , May 2005

Relevance of high-dose chemotherapy in solid tumours

References 

  1. Weiss RB, Gill GG, Hudis CA. An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications. J Clin Oncol. 2001;19:2771–2777
  2. Weiss RB, Rifkin RM, Stewart FM, et al. High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. Lancet. 2000;355:999–1003
  3. Rodenhuis S, Bontenbal M, Beex LV, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med. 2003;349:7–16
  4. Roche HH, Pouillart P, Meyer N, et al. Adjuvant high dose chemotherapy (HDC) improves early outcome for high risk (N>7) breast cancer patients: The Pegase 01 Trial. Proc Am Soc Clin Oncol. 2001;abstract 102
  5. Nitz UA, Frick M, Mohrmann S, et al. Tandem high dose chemotherapy versus dose-dense conventional chemotherapy for patients with high risk breast cancer: interim results from a multicenter phase III trial. Proc Am Soc Clin Oncol. 2003;abstract 3344
  6. Frei E, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980;69:585–594
  7. Frei E, Cucchi CA, Rosowsky A, et al. Alkylating agent resistance: in vitro studies with human cell lines. Proc Natl Acad Sci USA. 1985;82:2158–2162
  8. Schabel FM, Trader MW, Laster WR, Wheeler GP, Witt MH. Patterns of resistance and therapeutic synergism among alkylating agents. Antibiot Chemother. 1978;23:200–215
  9. Teicher BA, Holden SA, Cucchi CA, et al. Combination of N,N′,N-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo. Cancer Res. 1988;48:94–100
  10. Frei E, Teicher BA, Holden SA, et al. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res. 1988;48:6417–6423
  11. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2:1281–1288
  12. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol. 1986;4:1162–1170
  13. Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol. 1987;5:756–767
  14. Lazarus HM, Reed MD, Spitzer TR, et al. High-dose i.v. thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep. 1987;71:689–695
  15. Armitage JO. Bone marrow transplantation. N Engl J Med. 1994;330:827–838
  16. Beyer J, Schwella N, Zingsem J, et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol. 1995;13:1328–1335
  17. Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet. 2000;356:1384–1391
  18. Fetscher S, Finke J, Engelhardt R, et al. Early-onset secondary malignancies after high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Ann Hematol. 1997;74:73–77
  19. Kroger N, Zander AR, Martinelli G, et al. Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation. Ann Oncol. 2003;14:554–558
  20. Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003;349:17–26
  21. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol. 1995;13:2483–2489
  22. Stadtmauer EA, O’Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med. 2000;342:1069–1076
  23. Stadtmauer EA, O’Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy (HDC) plus autologous stem-cell transplantation (SCT) for metastatic breast cancer: 5-year update of the Philadelphia trial (PBT-1). Proc Am Soc Clin Oncol. 2002;abstract 169
  24. Peters WP, Jones RB, Vredenburgh JJ, et al. A large, prospective randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction chemotherapy (AFM). Proc Am Soc Clin Oncol. 1996;abstract 149
  25. Lotz J-P, Curé H, Janvier M, et al. High-dose chemotherapy (HD-CT) with hematopoietic stem cells transplantation (HSCT) for metastatic breast cancer (MBC): Results of the French protocol Pegase 04. Proc Am Soc Clin Oncol. 1999;abstract 161
  26. Biron P, Durand M, Roche H, et al. High-dose thiotepa (TTP), cyclophosphamide (CPM) and stem cell transplantation after 4 FEC 100 compared with 4 FEC alone allowed a better disease free survival but the same overall survival in first line chemotherapy for metastatic breast cancer. Results of the PEGASE 03 French Protocole. Proc Am Soc Clin Oncol. 2002;abstract 167
  27. Crown JP, Perey L, Lind M, et al. Superiority of tandem high-dose chemotherapy (HDC) versus optimized conventionally-dosed chemotherapy (CDC) in patients (pts) with metastatic breast cancer (MBC): The International Randomized Breast Cancer Dose Intensity Study (IBDIS 1). Proc Am Soc Clin Oncol. 2003;abstract 88
  28. Berry DA, Broadwater G, Klein JP, et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2002;20:743–750
  29. Nieto Y, Nawaz S, Jones RB, et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol. 2002;20:707–718
  30. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–3636
  31. Brito RA, Valero V, Buzdar AU, et al. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 2001;19:628–633
  32. Weiss RB, Woolf SH, Demakos E, et al. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. J Clin Oncol. 2003;21:1825–1835
  33. Bezwoda WR. Randomised, controlled trial of high-dose chemotherapy (HD-CNVp) versus standard dose (CAF) chemotherapy for high-risk, surgically treated, primary breast cancer. Proc Am Soc Clin Oncol. 1999;abstract 4
  34. Hortobagyi GN, Buzdar AU, Theriault RL, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000;92:225–233
  35. Rodenhuis S, Richel DJ, Van der Wall E, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet. 1998;352:515–521
  36. Zander AR, Kroger N, Schmoor C, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol. 2004;
  37. Leonard RC, Lind M, Twelves C, et al. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst. 2004;96:1076–1083
  38. Gianni A, Bonadonna G. Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with >3 positive nodes (LN). Proc Am Soc Clin Oncol. 2001;abstract 80
  39. Tokuda Y, Tajima T, Narabayashi M, et al. Randomized phase III study of high-dose chemotherapy (HDC) with autologous stem cell support as consolidation in high-risk postoperative breast cancer: Japan Clinical Oncology Group (JCOG9208). Proc Am Soc Clin Oncol. 2001;abstract 148
  40. Bliss JM, Vigushin D, Kanfer E, et al. Randomised trial of high dose therapy using cyclophosphamide, thiotepa and carboplatin in primary breast cancer patients with 4 or more histologically involved positive nodes (ISRCTN: 52623943). Proc Am Soc Clin Oncol. 2003;abstract 58
  41. Basser R, O’Neill A, Martinelli G, et al. Randomized trial comparing up-front, multi-cycle dose-intensive chemotherapy (CT) versus standard dose CT in women with high-risk stage 2 or 3 breast cancer (BC): First results from IBCSG Trial 15–95. Proc Am Soc Clin Oncol. 2003;abstract 20
  42. Schrama JG, Faneyte IF, Schornagel JH, et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol. 2002;13:689–698
  43. Bergh J. Long-term follow-up of the randomized Scandinavian Breast Group (SBG) study 9401 comparing standard FEC followed by marrow supported high dose therapy versus tailored and dose-escalated FEC therapy. Proc Am Soc Clin Oncol. 2003;abstract 94
  44. Peters WP. A prospective, randomized comparison of two doses of alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol. 1999;abstract 2
  45. Nikcevich D, Vredenburgh JJ, Broadwater G, et al. Ten year follow-up after high-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. Proc Am Soc Clin Oncol. 2002;abstract 1657
  46. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node- positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332:901–906
  47. Harstrick A, Schmoll HJ, Wilke H, et al. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol. 1991;9:1549–1555
  48. Loehrer PJ, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998;16:2500–2504
  49. McCaffrey JA, Mazumdar M, Bajorin DF, et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol. 1997;15:2559–2563
  50. Nichols CR, Tricot G, Williams SD, et al. Dose-intensive chemotherapy in refractory germ cell cancer – a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol. 1989;7:932–939
  51. Bhatia S, Abonour R, Porcu P, et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol. 2000;18:3346–3351
  52. Broun ER, Nichols CR, Gize G, et al. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer. 1997;79:1605–1610
  53. Gerl A, Clemm C, Schmeller N, et al. Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer. 1995;72:1026–1032
  54. Josefsen D, Ous S, Hoie J, et al. Salvage treatment in male patients with germ cell tumours. Br J Cancer. 1993;67:568–572
  55. Saxman SB, Nichols CR, Einhorn LH. Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. J Clin Oncol. 1994;12:1390–1393
  56. Beyer J, Stenning S, Gerl A, et al. High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann Oncol. 2002;13:599–605
  57. Vaena DA, Abonour R, Einhorn LH. Long-term survival after high-dose salvage chemotherapy for germ-cell malignancies with adverse prognostic variables. Proc Am Soc Clin Oncol. 2003;abstract 1538
  58. Rosti G, Pico JL, Wandt H, et al. High-dose chemotherapy (HDC) in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors (GCT); first results of a prospective randomised trial of the European Group for Blood and Marrow Transplantation (EBMT): IT-94 study. Proc Am Soc Clin Oncol. 2002;abstract 716
  59. Rodenhuis S, de Wit R, de Mulder PH, et al. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol. 1999;10:1467–1473
  60. Ayash LJ, Clarke M, Silver SM, et al. Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literature review. Bone Marrow Transplant. 2001;27:939–947
  61. Margolin BK, Doroshow JH, Ahn C, et al. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol. 1996;14:2631–2637
  62. Motzer RJ, Mazumdar M, Sheinfeld J, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol. 2000;18:1173–1180
  63. Rick O, Bokemeyer C, Beyer J, et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol. 2001;19:81–88
  64. Shamash J, O’Doherty CA, Oliver RT, et al. Should high-dose chemotherapy be used to consolidate second or third line treatment in relapsing germ cell tumours?. Acta Oncol. 2000;39:857–863
  65. Donadio AC, Sheinfeld J, Bacik J, et al. Paclitaxel, ifosfamide, and cisplatin (TIP): An effective second-line therapy for patients (pts) with relapsed testicular germ cell tumors (GCT. Proc Am Soc Clin Oncol. 2003;abstract 1537
  66. Bokemeyer C, Harstrick A, Beyer J, et al. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. Semin Oncol. 1998;25:24–32
  67. Decatris MP, Wilkinson PM, Welch RS, et al. High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicity. Ann Oncol. 2000;11:427–434
  68. Bokemeyer C, Kollmannsberger C, Meisner C, et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol. 1999;17:3450–3456
  69. Chevreau C, Droz JP, Pico JL, et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial. Eur Urol. 1993;23:213–217
  70. Grenman SE, Rantanen VT, Salmi TA. High-dose chemotherapy with autologous stem cell support in advanced ovarian cancer. Ann Med. 1996;28:151–158
  71. de Vries EG, Hamilton TC, Lind M, et al. Advanced ovarian cancer. Drug resistance, supportive care and dose intensity. Ann Oncol. 1993;4(Suppl 4):57–62
  72. Stiff PJ, Bayer R, Kerger C, et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol. 1997;15:1309–1317
  73. Stiff PJ, Veum-Stone J, Lazarus HM, et al. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. Ann Intern Med. 2000;133:504–515
  74. Ledermann JA, Herd R, Maraninchi D, et al. High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2001;12:693–699
  75. Pujade-Lauraine E, Cure H, Battista C, et al. High dose chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2001;11(Suppl 1):64–67
  76. Cure H, Battista C, Guastalla JP, et al. Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (AOC): preliminary results of a GINECO/ FNCLCC/ SFGM-TC study. Proc Am Soc Clin Oncol. 2001;abstract 815
  77. Lucidarme N, Valteau-Couanet D, Oberlin O, et al. Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors. Bone Marrow Transpl. 1998;22:535–540
  78. Bokemeyer C, Franzke A, Hartmann JT, et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer. 1997;80:1221–1227
  79. Dumontet C, Biron P, Bouffet E, et al. High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases. Bone Marrow Transpl. 1992;10:405–408
  80. Elias AD, Ayash LJ, Eder JP, et al. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol. 1991;9:320–327
  81. Mesia R, Sola C, Lopez PA, et al. High-dose chemotherapy and autologous bone marrow transplantation in high-grade metastatic sarcomas. Rev Clin Esp. 1994;194:960–965
  82. Blay JY, Bouhour D, Ray-Coquard I, et al. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol. 2000;18:3643–3650
  83. Atra A, Whelan JS, Calvagna V, et al. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing’s sarcoma. Bone Marrow Transpl. 1997;20:843–846
  84. Burdach S, Jurgens H, Peters C, et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing’s sarcoma. J Clin Oncol. 1993;11:1482–1488
  85. Burdach S, van Kaick B, Laws HJ, et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol. 2000;11:1451–1462
  86. Hartmann O, Oberlin O, Beaujean F, et al. Role of high-dose chemotherapy followed by bone marrow autograft in the treatment of metastatic Ewing’s sarcoma in children. Bull Cancer. 1990;77:181–187
  87. Horowitz ME, Kinsella TJ, Wexler LH, et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing’s sarcoma and rhabdomyosarcoma. J Clin Oncol. 1993;11:1911–1918
  88. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet. 1993;342:19–21
  89. Fetscher S, Brugger W, Engelhardt R, et al. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer. Ann Oncol. 1997;8:57–64
  90. Humblet Y, Symann M, Bosly A, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol. 1987;5:1864–1873
  91. Lorigan P, Woll P, O’Brien M, et al. Randomised phase 3 trial of dose dense ICE chemotherapy versus standard ICE in good prognosis small cell lung cancer (SCLC). Proc Am Soc Clin Oncol. 2003;abstract 2490
  92. Pratt CB, Epelman S, Jaffe N. Bleomycin, cyclophosphamide, and dactinomycin in metastatic osteosarcoma: lack of tumor regression in previously treated patients. Cancer Treat Rep. 1987;71:421–423
  93. Fagioli F, Aglietta M, Tienghi A, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol. 2002;20:2150–2156
  94. Linassier C, Ben Hassel M, Figarella-Branger D, et al. Phase III study comparing high-dose BCNU with autologous blood stem cell support versus standard dose BCNU, in combination with radiotherapy after gross total resection in patients with supratentorial glioblastoma. Proc Am Soc Clin Oncol. 2003;
  95. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med. 1999;341:1165–1173
  96. Al Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983–3988
  97. van de Vijver MJ, He YD, van t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009
  98. Elias AD, Ibrahim J, Richardson P, et al. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program. Biol Blood Marrow Transpl. 2002;8:198–205
  99. Bregni M, Dodero A, Peccatori J, et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood. 2002;99:4234–4236
  100. Pedrazzoli P, Da Prada GA, Giorgiani G, et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer. 2002;94:2409–2415
  101. Ueno NT, Rondon G, Mirza NQ, et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998;16:986–993

PII: S0305-7372(05)00030-7

doi: 10.1016/j.ctrv.2005.02.002

Cancer Treatment Reviews
Volume 31, Issue 3 , Pages 210-225 , May 2005

Article Tools